

変形性関節症
レポート②

変形性膝関節症に
対する間葉系
細胞療法

Table 1 Baseline and follow-up parameters of the four patients

	Mr. AA (base- line)		Mr. AA (6 months)		Ms. PZ (baseline)		Ms. PZ (6 months)		Mr. HM (baseline)		Mr. HM (6 months)		Ms. MS (base- line)		Ms. MS (6 months)	
Age (years)	55				57				65				54			
Duration of OA (years)	7				15											
BMI	28.5				29.7				25.71				37.1			
Walking time†	20		25		0		60		1		6		10		10	
Number of stairs‡	5		10		3		70		1		15		8		20	
Rest time to gelling pain§	15		30		15		30		0		0		15		15	
Pain on VAS	90		50		80		40		90		55		85		65	
Knee MSC transplant	Left	Right	Left	Right	Left	Right	Left	Right	Left	Right	Left	Right	Left	Right	Left	Right
Flexion contracture	-	-	-	-	10°	15°	5	10	10	5	5	10	-	-	-	-
Flexion¶	140°	140°	140°	140°	80°	90°	80°	100°	90°	120°	100°	120°	140°	140°	140°	140°
Creptus	1+	1+	-	-	-	4+	-	1+	3+	2+	+	+	4+	3+	3+	1+
Swelling	-	-	-	-	-	-	±	-	±	-	-	-	-	-	-	-
Instability	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

†Time to walk for the pain to appear (min). ‡Number of stairs to climb for the pain to appear. §Time to rest for gelling pain to appear (min). ¶Normal flexion: 140°. OA, osteoarthritis; BMI, body mass index; VAS, visual analogue scale; MSC, mesenchymal stem cell.

Fereydoun DAVATCHI, et al.
Mesenchymal stem cell therapy
for knee osteoarthritis.
Preliminary report of four
patients
International Journal of
Rheumatic Diseases 2011; 14:
211-215